Michael Borrelli
Concepts (206)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Microbubbles | 4 | 2012 | 25 | 1.300 |
Why?
| Sesquiterpenes | 3 | 2017 | 90 | 0.780 |
Why?
| Stroke | 7 | 2014 | 492 | 0.700 |
Why?
| Glioblastoma | 2 | 2021 | 91 | 0.680 |
Why?
| Aminopyrine | 1 | 2018 | 2 | 0.650 |
Why?
| Dactinomycin | 1 | 2018 | 22 | 0.650 |
Why?
| Growth Inhibitors | 1 | 2018 | 27 | 0.640 |
Why?
| Microinjections | 1 | 2018 | 29 | 0.640 |
Why?
| Calibration | 1 | 2018 | 58 | 0.630 |
Why?
| Antibiotics, Antineoplastic | 1 | 2018 | 78 | 0.610 |
Why?
| Microscopy, Fluorescence | 1 | 2018 | 162 | 0.600 |
Why?
| Pancreatic Neoplasms | 1 | 2018 | 213 | 0.530 |
Why?
| Ultrasonic Therapy | 2 | 2011 | 32 | 0.480 |
Why?
| Fluorocarbons | 4 | 2016 | 45 | 0.470 |
Why?
| Thrombolytic Therapy | 2 | 2011 | 111 | 0.450 |
Why?
| High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 14 | 0.430 |
Why?
| Mechanical Thrombolysis | 1 | 2012 | 8 | 0.430 |
Why?
| Blood Coagulation | 1 | 2012 | 57 | 0.420 |
Why?
| Acetylcysteine | 1 | 2011 | 100 | 0.390 |
Why?
| Liver Failure, Acute | 1 | 2011 | 53 | 0.390 |
Why?
| Serum Albumin | 1 | 2011 | 58 | 0.380 |
Why?
| Brain Ischemia | 2 | 2014 | 161 | 0.370 |
Why?
| Rabbits | 9 | 2016 | 370 | 0.360 |
Why?
| Glucose | 1 | 2011 | 340 | 0.330 |
Why?
| Acetaminophen | 1 | 2011 | 282 | 0.320 |
Why?
| Magnetic Resonance Imaging | 2 | 2014 | 1533 | 0.310 |
Why?
| Animals | 19 | 2023 | 13150 | 0.310 |
Why?
| Fluorescent Dyes | 3 | 2022 | 101 | 0.300 |
Why?
| Radiation-Sensitizing Agents | 2 | 2023 | 53 | 0.290 |
Why?
| Neuroprotective Agents | 3 | 2016 | 105 | 0.260 |
Why?
| Surface Properties | 2 | 2018 | 72 | 0.250 |
Why?
| Hyperthermia, Induced | 2 | 2007 | 118 | 0.250 |
Why?
| Heat-Shock Proteins | 2 | 2002 | 99 | 0.250 |
Why?
| Hematologic Neoplasms | 2 | 2017 | 99 | 0.250 |
Why?
| Structure-Activity Relationship | 5 | 2017 | 394 | 0.240 |
Why?
| Cell Line, Tumor | 5 | 2021 | 1402 | 0.230 |
Why?
| Cerebral Angiography | 3 | 2012 | 96 | 0.220 |
Why?
| Nanostructures | 1 | 2023 | 47 | 0.220 |
Why?
| Neoplasm Proteins | 2 | 2002 | 323 | 0.220 |
Why?
| Metal Nanoparticles | 1 | 2023 | 83 | 0.210 |
Why?
| Liposomes | 1 | 2022 | 48 | 0.210 |
Why?
| Disease Models, Animal | 6 | 2014 | 1451 | 0.210 |
Why?
| Drug Synergism | 2 | 2018 | 150 | 0.210 |
Why?
| Adenoviridae | 1 | 2002 | 51 | 0.200 |
Why?
| Tissue Plasminogen Activator | 3 | 2011 | 110 | 0.200 |
Why?
| Particle Size | 2 | 2012 | 75 | 0.200 |
Why?
| Tumor Cells, Cultured | 2 | 2018 | 465 | 0.200 |
Why?
| Molecular Structure | 3 | 2017 | 297 | 0.200 |
Why?
| Biological Specimen Banks | 1 | 2021 | 21 | 0.200 |
Why?
| Genetic Vectors | 1 | 2002 | 127 | 0.200 |
Why?
| Organoids | 1 | 2021 | 39 | 0.190 |
Why?
| Dose-Response Relationship, Drug | 4 | 2017 | 1374 | 0.190 |
Why?
| Drug Discovery | 1 | 2021 | 85 | 0.190 |
Why?
| Antiviral Agents | 1 | 2002 | 174 | 0.180 |
Why?
| Cell Proliferation | 4 | 2017 | 1007 | 0.180 |
Why?
| Antineoplastic Agents | 3 | 2021 | 1172 | 0.180 |
Why?
| Indoles | 2 | 2017 | 278 | 0.180 |
Why?
| Emulsions | 3 | 2014 | 24 | 0.180 |
Why?
| Apoptosis | 3 | 2023 | 1100 | 0.170 |
Why?
| Brain Neoplasms | 2 | 2021 | 286 | 0.170 |
Why?
| Neoplasms | 2 | 2022 | 1233 | 0.170 |
Why?
| Dextrans | 1 | 2018 | 16 | 0.160 |
Why?
| Rats | 5 | 2016 | 3300 | 0.160 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 36 | 0.160 |
Why?
| Fluorescence | 1 | 2018 | 41 | 0.160 |
Why?
| Drug Combinations | 1 | 2018 | 123 | 0.160 |
Why?
| Prostatic Neoplasms | 1 | 2002 | 396 | 0.150 |
Why?
| Radiology, Interventional | 1 | 2018 | 31 | 0.150 |
Why?
| Adenocarcinoma | 1 | 2002 | 401 | 0.150 |
Why?
| Femur Head Necrosis | 1 | 2017 | 18 | 0.150 |
Why?
| Oxidative Stress | 1 | 2002 | 768 | 0.150 |
Why?
| Femur Head | 1 | 2017 | 26 | 0.150 |
Why?
| Osteonecrosis | 1 | 2017 | 34 | 0.150 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 136 | 0.150 |
Why?
| Carboxylic Acids | 1 | 2017 | 17 | 0.150 |
Why?
| Brain | 3 | 2016 | 1309 | 0.150 |
Why?
| Esters | 1 | 2017 | 22 | 0.150 |
Why?
| Treatment Outcome | 3 | 2012 | 5138 | 0.140 |
Why?
| Rats, Inbred F344 | 1 | 2016 | 196 | 0.140 |
Why?
| Glucocorticoids | 1 | 2017 | 219 | 0.130 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 69 | 0.130 |
Why?
| Humans | 15 | 2022 | 49827 | 0.130 |
Why?
| Biomedical Research | 1 | 2018 | 231 | 0.130 |
Why?
| Stilbenes | 1 | 2015 | 62 | 0.120 |
Why?
| Triazoles | 1 | 2015 | 107 | 0.120 |
Why?
| Positron-Emission Tomography | 1 | 2016 | 294 | 0.120 |
Why?
| Recombinant Fusion Proteins | 3 | 2011 | 182 | 0.120 |
Why?
| Intracranial Embolism | 2 | 2012 | 27 | 0.120 |
Why?
| Cerebral Hemorrhage | 2 | 2011 | 104 | 0.110 |
Why?
| Cerebral Infarction | 1 | 2013 | 39 | 0.110 |
Why?
| Hot Temperature | 3 | 2004 | 208 | 0.110 |
Why?
| Blood | 1 | 2012 | 28 | 0.110 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.100 |
Why?
| Antidotes | 1 | 2011 | 29 | 0.100 |
Why?
| Tissue Distribution | 3 | 2022 | 164 | 0.100 |
Why?
| Radiation Dosage | 1 | 2012 | 157 | 0.100 |
Why?
| Statistics as Topic | 1 | 2011 | 89 | 0.100 |
Why?
| Anilino Naphthalenesulfonates | 1 | 2011 | 5 | 0.100 |
Why?
| Ultrasonics | 1 | 2011 | 28 | 0.100 |
Why?
| Microscopy, Fluorescence, Multiphoton | 1 | 2011 | 6 | 0.100 |
Why?
| Protein Folding | 1 | 2011 | 49 | 0.100 |
Why?
| Analgesics, Non-Narcotic | 1 | 2011 | 116 | 0.090 |
Why?
| Fibrinolytic Agents | 1 | 2011 | 125 | 0.090 |
Why?
| Stress, Physiological | 1 | 2011 | 170 | 0.090 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 854 | 0.080 |
Why?
| Ultrasonography | 1 | 2011 | 436 | 0.080 |
Why?
| HSP70 Heat-Shock Proteins | 2 | 2011 | 62 | 0.080 |
Why?
| Proteins | 1 | 2011 | 341 | 0.080 |
Why?
| Reproducibility of Results | 1 | 2011 | 1188 | 0.080 |
Why?
| Male | 6 | 2017 | 25093 | 0.070 |
Why?
| Mitosis | 1 | 2007 | 92 | 0.070 |
Why?
| Mice | 2 | 2017 | 5720 | 0.070 |
Why?
| HSP27 Heat-Shock Proteins | 2 | 2002 | 7 | 0.070 |
Why?
| Luminescent Proteins | 2 | 2002 | 53 | 0.060 |
Why?
| Green Fluorescent Proteins | 2 | 2002 | 90 | 0.060 |
Why?
| Molecular Chaperones | 2 | 2002 | 64 | 0.060 |
Why?
| Colonic Neoplasms | 1 | 2007 | 162 | 0.060 |
Why?
| Calcium-Transporting ATPases | 1 | 2004 | 14 | 0.060 |
Why?
| Muscle Fibers, Fast-Twitch | 1 | 2004 | 14 | 0.060 |
Why?
| Halogens | 1 | 2022 | 4 | 0.050 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 11 | 0.050 |
Why?
| Lipid Bilayers | 1 | 2022 | 11 | 0.050 |
Why?
| Chloral Hydrate | 1 | 2022 | 19 | 0.050 |
Why?
| Indicators and Reagents | 1 | 2002 | 36 | 0.050 |
Why?
| Gold | 1 | 2023 | 135 | 0.050 |
Why?
| Mammals | 1 | 2002 | 56 | 0.050 |
Why?
| Nucleoside Deaminases | 1 | 2002 | 4 | 0.050 |
Why?
| Cytosine Deaminase | 1 | 2002 | 8 | 0.050 |
Why?
| Heat-Shock Response | 1 | 2002 | 28 | 0.050 |
Why?
| Flucytosine | 1 | 2002 | 14 | 0.050 |
Why?
| Thymidine Kinase | 1 | 2002 | 19 | 0.050 |
Why?
| Ganciclovir | 1 | 2002 | 24 | 0.050 |
Why?
| Herpesvirus 1, Human | 1 | 2002 | 15 | 0.050 |
Why?
| Gene Transfer Techniques | 1 | 2002 | 37 | 0.050 |
Why?
| Protons | 1 | 2022 | 69 | 0.050 |
Why?
| Polyethylene Glycols | 1 | 2022 | 96 | 0.050 |
Why?
| Cholesterol | 1 | 2022 | 146 | 0.050 |
Why?
| Spheroids, Cellular | 1 | 2021 | 25 | 0.050 |
Why?
| Tissue Culture Techniques | 1 | 2021 | 40 | 0.050 |
Why?
| Shock | 1 | 2002 | 35 | 0.050 |
Why?
| Cell Nucleus | 1 | 2002 | 184 | 0.050 |
Why?
| Radiotherapy | 1 | 2002 | 128 | 0.050 |
Why?
| Phosphorylation | 1 | 2002 | 536 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2002 | 234 | 0.050 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 268 | 0.050 |
Why?
| Fibroblasts | 1 | 2002 | 343 | 0.040 |
Why?
| Cell Survival | 1 | 2002 | 598 | 0.040 |
Why?
| Gene Expression | 1 | 2002 | 608 | 0.040 |
Why?
| Advisory Committees | 1 | 2018 | 63 | 0.040 |
Why?
| Kidney | 1 | 2002 | 665 | 0.040 |
Why?
| Consensus | 1 | 2018 | 143 | 0.040 |
Why?
| Societies, Medical | 1 | 2018 | 175 | 0.040 |
Why?
| Injections, Intravenous | 1 | 2016 | 140 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 67 | 0.040 |
Why?
| Rats, Sprague-Dawley | 2 | 2014 | 1595 | 0.030 |
Why?
| Lung Neoplasms | 1 | 2002 | 605 | 0.030 |
Why?
| Gliosarcoma | 1 | 2015 | 5 | 0.030 |
Why?
| Tumor Stem Cell Assay | 1 | 2015 | 17 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2016 | 376 | 0.030 |
Why?
| Dimerization | 1 | 2015 | 53 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2015 | 61 | 0.030 |
Why?
| Stereoisomerism | 1 | 2015 | 104 | 0.030 |
Why?
| Bone Density | 1 | 2017 | 379 | 0.030 |
Why?
| Molecular Docking Simulation | 1 | 2015 | 73 | 0.030 |
Why?
| Brain Infarction | 1 | 2014 | 12 | 0.030 |
Why?
| Osteogenesis | 1 | 2017 | 351 | 0.030 |
Why?
| Carotid Artery, Common | 1 | 2014 | 44 | 0.030 |
Why?
| Osteoblasts | 1 | 2017 | 449 | 0.030 |
Why?
| Middle Cerebral Artery | 1 | 2014 | 35 | 0.030 |
Why?
| Osteoclasts | 1 | 2017 | 425 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 2015 | 184 | 0.030 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2015 | 183 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2017 | 1806 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 197 | 0.020 |
Why?
| Organelles | 1 | 2011 | 17 | 0.020 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2011 | 24 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2011 | 282 | 0.020 |
Why?
| Random Allocation | 1 | 2011 | 280 | 0.020 |
Why?
| HeLa Cells | 1 | 2011 | 251 | 0.020 |
Why?
| Cell Line | 2 | 2004 | 1002 | 0.020 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 104 | 0.020 |
Why?
| Homeostasis | 1 | 2011 | 199 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 565 | 0.020 |
Why?
| Radiography | 1 | 2010 | 489 | 0.020 |
Why?
| Female | 3 | 2016 | 26329 | 0.020 |
Why?
| HCT116 Cells | 1 | 2007 | 22 | 0.020 |
Why?
| Time Factors | 1 | 2013 | 2912 | 0.020 |
Why?
| Protein Conformation | 1 | 2007 | 166 | 0.020 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2004 | 8 | 0.020 |
Why?
| Sarcoplasmic Reticulum | 1 | 2004 | 21 | 0.020 |
Why?
| Thermodynamics | 1 | 2004 | 34 | 0.020 |
Why?
| Multiprotein Complexes | 1 | 2004 | 23 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2007 | 436 | 0.010 |
Why?
| Transfection | 1 | 2004 | 357 | 0.010 |
Why?
| Models, Molecular | 1 | 2004 | 337 | 0.010 |
Why?
| Transcription Factors | 1 | 2007 | 563 | 0.010 |
Why?
| Kinetics | 1 | 2004 | 626 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2004 | 486 | 0.010 |
Why?
| Protein Binding | 1 | 2004 | 660 | 0.010 |
Why?
| Calcium | 1 | 2004 | 397 | 0.010 |
Why?
| Octoxynol | 1 | 2002 | 6 | 0.010 |
Why?
| Detergents | 1 | 2002 | 16 | 0.010 |
Why?
| Solubility | 1 | 2002 | 68 | 0.010 |
Why?
| Dogs | 1 | 2002 | 182 | 0.010 |
Why?
| Protein Processing, Post-Translational | 1 | 2002 | 171 | 0.010 |
Why?
| Epithelial Cells | 1 | 2002 | 209 | 0.010 |
Why?
|
|
Borrelli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|